Fournier's European Strategy
Executive Summary
To reduce its dependence on a stagnant and price sensitive French market, Fournier has created a low-risk R&D program coupled with an aggressive international acquisition program. The program attempts to take advantage of small-market research opportunities as well as acquisition targets overlooked by large companies or which fall out of mega-mergers. Is this gamble enough to ensure independence for a mid-sized player?
You may also be interested in...
Nous Voici! Sanofi's Leap to the World Stage
Still as French as they come, Sanofi's extraordinary international success--its P/E and growth rate are among the industry's highest--has been due to two factors. The first is its productive research group, which has eschewed most biotech fashions in favor of a conservative, small-molecule, therapeutically focused R&D program. The second has been its joint venture with Bristol-Myers on two of its most important products, a joint venture which allowed Sanofi, in a protected fashion, to learn to compete internationally against the most powerful pharmaceutical marketers in the world. If the company has an Achilles' heel, it is the francocentrism of its marketing and development, and perhaps research as well.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.